Encouraging to hear that PEPFAR and the Global Fund will support expanding access to lenacapavir for an additional 1 million users, bringing the total commitment to 3 million people. This represents a significant step forward for HIV prevention efforts globally. We would be very interested to hear any ground-level experiences or early impressions regarding the use of lenacapavir.
Link to news: PEPFAR and The Global Fund Make Additional Investment in Gilead's Lenacapavir for HIV Prevention to Further Expand Access
------------------------------
Sravan Kumar Patel Ph.D.
Associate Professor
University of Pittsburgh
Mars PA
[email protected]Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------